@article{JTD14502,
author = {Cai Xu and Steven Hsesheng Lin},
title = {Deciding on the neoadjuvant approach for esophageal adenocarcinomas},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {7},
year = {2017},
keywords = {},
abstract = {Surgery alone has long been the single most effective treatment modality for the management of esophageal cancer. However, despite modern advances in surgical techniques, the 5-year survival with surgery alone is only in the range of 16–33% (1,2). The addition of neoadjuvant therapy, whether it is neoadjuvant chemoradiotherapy (NCRT) or neoadjuvant chemotherapy (NCT), can significantly improve clinical outcomes compared with surgery alone. In studies using NCRT, a higher complete resection rate can be achieved compared to surgery (80–92% vs. 59–69%) (2,3), as well as the pathologic complete response (pCR) rate, ranging from 16% to 33% (1-4), which can be an independent favorable prognostic factor (5,6).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14502}
}